|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
18 April 2017 |
|
Main ID: |
ChiCTR-OCH-11001198 |
|
Date of registration:
|
2011-03-08 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
DNA pooling-based genome-wide screen for genetic determinants of response to antiplatelet therapy after PCI and validation
|
|
Scientific title:
|
DNA pooling-based genome-wide screen for genetic determinants of response to antiplatelet therapy after PCI and validation |
|
Date of first enrolment:
|
2011-01-01 |
|
Target sample size:
|
Total:3500; |
|
Recruitment status: |
Completed |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=8341 |
|
Study type:
|
Observational study |
|
Study design:
|
Cohort study
|
|
Phase:
|
Post-market
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Shi-Long Zhong
|
|
Address:
|
106 Zhongshan Road, Guangzhou, Guangdong, China
510080
|
|
Telephone:
|
+86 20 83827812-51157 |
|
Email:
|
zhongshilong@gmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Shi-Long Zhong
|
|
Address:
|
106 Zhongshan Road, Guangzhou, Guangdong, China
510080
|
|
Telephone:
|
+86 20 83827812-51157 |
|
Email:
|
zhongshilong@gmail.com |
|
Affiliation:
|
Guangdong General Hospital, Guangdong Academy of Medical Sciences |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Coronary artery disease patients who undergo primary percutaneous coronary intervention and clopidogrel treatment
Exclusion criteria: 1. Patients who are concomitant using oral coumarin derivates or other anticoagulant treatment and with INR larger than 1.5, 10 days before operation;
2. Any contraindication to aspirin or clopidogrel therapy;
3. Patients with pre-existing bleeding disorders;
4. Known bleeding disorders;
5. Subject is pregnant or lactating or planning to become pregnant.
Age minimum:
18
Age maximum:
85
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Coronary artery disease
|
|
Intervention(s)
|
|
Total:Clopidogrel, interacting drugs, genetic variation, plasma biomarker ;
|
|
Primary Outcome(s)
|
|
Major adverse cardiac events;
|
|
Secondary Outcome(s)
|
|
Bleeding events;
|
|
Source(s) of Monetary Support
|
|
National Natural Science Foundation of China
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|